VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC. et al

  1. September 20, 2023

    Takeda Settles Gout Drug Antitrust Case Midtrial

    Takeda Pharmaceuticals USA Inc. has reached a settlement with drug wholesalers in the middle of an antitrust trial in Pennsylvania federal court over the delayed entry of a generic version of its gout drug Colcrys, according to court filings.

  2. September 19, 2023

    Takeda Wants End To Gout Drug Antitrust Case Midtrial

    Takeda Pharmaceuticals is seeking an early end to an ongoing trial in an antitrust case brought by drug wholesalers over the delayed entry of a generic version of its gout drug Colcrys, claiming that underlying patent litigation and that lack of solid evidence pointing to a price-fixing conspiracy torpedo the plaintiffs' case.

  3. September 06, 2023

    Wholesalers Tell Pa. Jury Takeda Delayed Generic Gout Drug

    Counsel for a group of drug wholesalers on Wednesday told a federal jury in Philadelphia that Takeda Pharmaceuticals USA Inc. cost them several hundred million dollars by arranging for generic drugmakers to hold off introducing off-brand versions of Takeda's gout medication Colcrys into the market.

  4. August 15, 2023

    Antitrust Watchers Are About To Have Their Hands Full

    A deluge of trials and key hearings are slated for the coming weeks in antitrust cases spread across the country, including the first expected trials for monopolization claims against Google, trials in a variety of other conduct cases from enforcers and private parties, and hearings on several merger challenges.

  5. August 04, 2023

    Pharma Cos. Can't Trim Gout Drug Antitrust Claims

    A Pennsylvania federal court has refused a bid from Takeda Pharmaceuticals and several generic-drug makers to trim claims from a suit alleging they struck anti-competitive deals to delay competition for Takeda's anti-gout drug Colcrys, ahead of a slated September trial.

  6. May 25, 2023

    Judge Lets Gout Drug Antitrust Suit Move Forward

    An antitrust suit accusing Takeda Pharmaceuticals of striking anti-competitive deals to beat back generic competition on its anti-gout drug Colcrys is teed up for trial after a Pennsylvania federal judge refused to decide any of the claims himself.

  7. March 01, 2023

    Class Cert. Denied Again In Gout Drug Antitrust Case

    A Pennsylvania federal court has again refused to certify a class of drug wholesalers accusing Takeda Pharmaceuticals and others of delaying generic competition for the anti-gout drug Colcrys, finding that it takes more than just a number to make a class.

  8. November 28, 2022

    Lack Of Facts Dooms Class Cert Over Takeda Gout Drug

    A federal judge last week rejected a bid by pharmacy chain Value Drug Co. to certify a class of roughly 50 purchasers of Takeda Pharmaceuticals' anti-gout drug Colcrys alleging that the company engaged in anticompetitive deals to stave off generic competition.

  9. January 04, 2022

    Generic Drug Cos., Takeda Escape Gout Drug Antitrust Suit

    A Pennsylvania federal judge threw out a lawsuit accusing drugmakers of participating in a conspiracy to delay a generic version of Takeda Pharmaceuticals' anti-gout drug Colcrys, telling pharmacy chain Value Drug Co. that its complaint lacked a plausible single horizontal conspiracy.

  10. November 02, 2021

    Generic-Drug Co. Wants Gout Drug Antitrust Suit Tossed

    Drugmaker Par Pharmaceutical Inc. told a Pennsylvania federal court it could not have participated in an alleged conspiracy to delay a generic version of Takeda Pharmaceuticals' anti-gout drug Colcrys because the FDA did not authorize Par's own version of the drug until this summer.